{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T18:10:04Z","timestamp":1754071804355,"version":"3.41.2"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"\nBackground<\/jats:title>\nAcute myeloid leukemia (AML) is a highly aggressive hematologic malignancy with dismal survival outcomes, where dysregulation of regulated cell death (RCD) pathways plays a pivotal role in leukemogenesis and therapeutic resistance.<\/jats:p>\n<\/jats:sec>\n\nMethods<\/jats:title>\nDifferential expression analyses were performed comparing AML samples with healthy bone marrow. Diagnostic differentially expressed genes (DEGs) were then intersected with curated gene sets representing apoptosis, pyroptosis, autophagy, necroptosis, and ferroptosis to derive an RCD-based gene signature. Prognostic markers were identified by univariate Cox regression, and these markers were refined using LASSO regression to construct a multi-gene prognostic model that generated an individual risk score (RS) for each patient. The performance of the model was validated internally through Kaplan\u2013Meier survival analyses and receiver operating characteristic (ROC) curves for 1-, 3-, and 5-year survival, and externally confirmed in an independent TARGET-AML cohort. In addition, mutation analysis was conducted using the maftools package, and immune infiltration profiling was performed with CIBERSORT and xCell to characterize the molecular landscape of the risk groups.<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nOur integrative approach yielded a four-gene prognostic model incorporating ARHGEF35, GSN, ELANE, and AKT3. High RS was strongly associated with adverse overall survival, with Kaplan\u2013Meier analyses showing p-value<\/jats:italic>\u2009<\u20090.0001 in the training cohort and p-value<\/jats:italic>\u2009=\u20090.0026 in the testing cohort. The model demonstrated robust predictive accuracy with AUC values of 82%, 87%, and 91% for 1-, 3-, and 5-year survival in the training set, and 65%, 81%, and 94% in the testing set. Mutation analysis revealed that DNMT3A and RUNX1 mutations were significantly enriched in high-RS patients (p-value<\/jats:italic>\u2009=\u20090.0015 and p-value<\/jats:italic>\u2009=\u20090.0086, respectively), whereas KIT mutations were more prevalent in low-RS patients (p-value<\/jats:italic>\u2009=\u20090.0058). Immune profiling indicated that high-RS patients had increased M2 macrophage infiltration (p-value<\/jats:italic>\u2009=\u20090.0027) and reduced resting mast cells (p-value<\/jats:italic>\u2009=\u20090.0033).<\/jats:p>\n<\/jats:sec>\n\nConclusion<\/jats:title>\nThese findings establish that an RCD-based multi-gene risk model can robustly stratify AML patients by prognosis and illuminate underlying genomic and immunologic mechanisms, thereby offering promising avenues for personalized therapeutic strategies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0328412","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T17:34:59Z","timestamp":1754069699000},"page":"e0328412","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Derivation of a novel multi\u2010gene prognostic model based on regulated cell death pathways in acute myeloid leukemia: A comprehensive bioinformatic analysis integrating gene expression, mutation profiling, and immune infiltration"],"prefix":"10.1371","volume":"20","author":[{"given":"Ali","family":"Ahmadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Abas","family":"Navidinia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davood","family":"Bashash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behzad","family":"Poopak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4143-2435","authenticated-orcid":true,"given":"Shadi","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"issue":"7","key":"pone.0328412.ref001","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3390\/cancers14071689","article-title":"Refining AML treatment: The role of genetics in response and resistance evaluation to new agents","volume":"14","author":"A Halik","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0328412.ref002","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"HM Kantarjian","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"pone.0328412.ref003","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"H D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"9","key":"pone.0328412.ref004","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"H D\u00f6hner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"pone.0328412.ref005","first-page":"103492","article-title":"Construction of a stromal-related prognostic model in acute myeloid leukemia by comprehensive bioinformatics analysis","volume":"73","author":"LK Hajipirloo","year":"2025","journal-title":"Curr Res Transl Med"},{"issue":"12","key":"pone.0328412.ref006","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"JP Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0328412.ref007","doi-asserted-by":"crossref","first-page":"151","DOI":"10.20517\/cdr.2022.108","article-title":"Targeting regulated cell death pathways in acute myeloid leukemia","volume":"6","author":"S Garciaz","year":"2023","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"pone.0328412.ref008","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"S Elmore","year":"2007","journal-title":"Toxicol Pathol"},{"key":"pone.0328412.ref009","doi-asserted-by":"crossref","first-page":"101130","DOI":"10.1016\/j.blre.2023.101130","article-title":"Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution","volume":"62","author":"E Santinelli","year":"2023","journal-title":"Blood Rev"},{"issue":"1","key":"pone.0328412.ref010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13045-022-01365-6","article-title":"The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy","volume":"15","author":"H Wang","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"pone.0328412.ref011","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-020-00946-7","article-title":"Ferroptosis, necroptosis, and pyroptosis in anticancer immunity","volume":"13","author":"R Tang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"10","key":"pone.0328412.ref012","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/15548627.2020.1822628","article-title":"The role of autophagy in targeted therapy for acute myeloid leukemia","volume":"17","author":"W Du","year":"2021","journal-title":"Autophagy"},{"issue":"6","key":"pone.0328412.ref013","first-page":"552","article-title":"Autophagy a close relative of AML biology","volume":"10","author":"C Joffre","year":"2021","journal-title":"Biology (Basel)"},{"key":"pone.0328412.ref014","doi-asserted-by":"crossref","first-page":"1275774","DOI":"10.3389\/fmolb.2023.1275774","article-title":"Susceptibility of acute myeloid leukemia cells to ferroptosis and evasion strategies","volume":"10","author":"H Zhang","year":"2023","journal-title":"Front Mol Biosci"},{"issue":"7","key":"pone.0328412.ref015","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"AM Newman","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"1","key":"pone.0328412.ref016","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"D Aran","year":"2017","journal-title":"Genome Biol"},{"issue":"1","key":"pone.0328412.ref017","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12964-023-01282-2","article-title":"The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways","volume":"21","author":"M Bakhtiyari","year":"2023","journal-title":"Cell Commun Signal"},{"issue":"8","key":"pone.0328412.ref018","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1200\/JCO.21.01548","article-title":"Response rate, event-free survival, and overall survival in newly diagnosed acute myeloid leukemia: US food and drug administration trial-level and patient-level analyses","volume":"40","author":"KJ Norsworthy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0328412.ref019","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41375-021-01425-9","article-title":"Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries","volume":"36","author":"C R\u00e9cher","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"pone.0328412.ref020","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14728220903136775","article-title":"Targeting the PI3K\/AKT\/mTOR signaling network in acute myelogenous leukemia","volume":"18","author":"AM Martelli","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"pone.0328412.ref021","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.3390\/ijms21082907","article-title":"The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells","volume":"21","author":"I Nepstad","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"9","key":"pone.0328412.ref022","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.3390\/jcm9092934","article-title":"Targeting PI3K\/Akt\/mTOR in AML: Rationale and clinical evidence","volume":"9","author":"S Darici","year":"2020","journal-title":"J Clin Med"},{"key":"pone.0328412.ref023","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jbior.2018.03.001","article-title":"Dual inhibition of PI3K\/mTOR signaling in chemoresistant AML primary cells","volume":"68","author":"J Bertacchini","year":"2018","journal-title":"Adv Biol Regul"},{"issue":"9","key":"pone.0328412.ref024","first-page":"10112","article-title":"CircMYC regulates the mitochondrial respiration and cell viability via miR-516a-5p\/AKT3 axis in acute myeloid leukemia","volume":"13","author":"X Zou","year":"2021","journal-title":"Am J Transl Res"},{"key":"pone.0328412.ref025","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12935-020-01468-5","article-title":"Tanshinone IIA regulates human AML cell proliferation, cell cycle, and apoptosis through miR-497-5p\/AKT3 axis","volume":"20","author":"Z-Y Nie","year":"2020","journal-title":"Cancer Cell Int"},{"issue":"1","key":"pone.0328412.ref026","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1038\/s41598-024-57578-x","article-title":"Differential prognostic values of the three AKT isoforms in acute myeloid leukemia","volume":"14","author":"E Corre","year":"2024","journal-title":"Sci Rep"},{"key":"pone.0328412.ref027","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jbior.2017.05.002","article-title":"Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia","volume":"65","author":"MR Ricciardi","year":"2017","journal-title":"Adv Biol Regul"},{"issue":"2","key":"pone.0328412.ref028","doi-asserted-by":"crossref","first-page":"89","DOI":"10.18632\/oncotarget.114","article-title":"The phosphatidylinositol 3-kinase\/Akt\/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients","volume":"1","author":"AM Martelli","year":"2010","journal-title":"Oncotarget"},{"key":"pone.0328412.ref029","doi-asserted-by":"crossref","first-page":"114384","DOI":"10.1016\/j.bcp.2020.114384","article-title":"Targeting Akt-associated microRNAs for cancer therapeutics","volume":"189","author":"MS Adil","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"19","key":"pone.0328412.ref030","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.3390\/ijms21197132","article-title":"Role of plasma gelsolin protein in the final stage of erythropoiesis and in correction of erythroid dysplasia in vitro","volume":"21","author":"SY Han","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0328412.ref031","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12944-017-0624-1","article-title":"Unexpected profile of sphingolipid contents in blood and bone marrow plasma collected from patients diagnosed with acute myeloid leukemia","volume":"16","author":"M W\u0105tek","year":"2017","journal-title":"Lipids Health Dis"},{"issue":"2","key":"pone.0328412.ref032","article-title":"Application of an artificial neural network in the diagnosis of chronic lymphocytic leukemia","volume":"11","author":"FS Aghamaleki","year":"2019","journal-title":"Cureus"},{"issue":"7","key":"pone.0328412.ref033","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3390\/cancers12071809","article-title":"Identification of GSN and LAMC2 as key prognostic genes of bladder cancer by integrated bioinformatics analysis","volume":"12","author":"J-L Yang","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"pone.0328412.ref034","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1134\/S1022795424020042","article-title":"Identification of low expression of GSN as a key prognosis gene in patients with gastric carcinoma","volume":"60","author":"M Hao","year":"2024","journal-title":"Russ J Genet"},{"issue":"1","key":"pone.0328412.ref035","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41392-021-00766-2","article-title":"ELANE: an emerging lane to selective anticancer therapy","volume":"6","author":"B Peng","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"14","key":"pone.0328412.ref036","article-title":"ELANE is a promising prognostic biomarker that mediates pyroptosis in gastric cancer","volume":"10","author":"M Cui","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"pone.0328412.ref037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/SHK.0000000000002137","article-title":"Construction of sepsis diagnostic models and identification of macrophage subpopulations based on pyroptosis-related genes","volume":"60","author":"Z Sun","year":"2023","journal-title":"Shock"},{"issue":"1","key":"pone.0328412.ref038","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12920-022-01339-0","article-title":"A pyroptosis-associated signature plays a role in prognosis prediction in clear cell renal cell carcinoma","volume":"15","author":"Z Li","year":"2022","journal-title":"BMC Med Genomics"},{"issue":"3","key":"pone.0328412.ref039","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00262-024-03922-z","article-title":"Neutrophil-induced pyroptosis promotes survival in patients with hepatoblastoma","volume":"74","author":"T Fu","year":"2025","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"pone.0328412.ref040","first-page":"3153","article-title":"ELANE is highly expressed in leukemia patients and predicts poor survival","volume":"12","author":"Y Zhao","year":"2019","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"pone.0328412.ref041","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/08820139.2022.2115379","article-title":"ELANE promotes M2 macrophage polarization by down-regulating PTEN and participates in the lung cancer progression","volume":"52","author":"S Song","year":"2023","journal-title":"Immunol Invest"},{"key":"pone.0328412.ref042","article-title":"Long-range somatic structural variation calling from matched tumor-normal co-assembly graphs","volume":"2024","author":"MK Le","year":"2024","journal-title":"bioRxiv"},{"issue":"4","key":"pone.0328412.ref043","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/cells8040351","article-title":"p190RhoGAPs, the ARHGAP35- and ARHGAP5-encoded proteins, in health and disease","volume":"8","author":"C H\u00e9raud","year":"2019","journal-title":"Cells"},{"issue":"6","key":"pone.0328412.ref044","doi-asserted-by":"crossref","first-page":"14605","DOI":"10.1080\/21655979.2022.2092677","article-title":"Rho GTPase-activating protein 35 suppresses gastric cancer metastasis by regulating cytoskeleton reorganization and epithelial-to-mesenchymal transition","volume":"13","author":"Y Sun","year":"2022","journal-title":"Bioengineered"},{"issue":"2","key":"pone.0328412.ref045","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030320","article-title":"DNMT3A in leukemia","volume":"7","author":"L Brunetti","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"24","key":"pone.0328412.ref046","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1182\/blood-2011-07-367961","article-title":"Mutant DNMT3A: A marker of poor prognosis in acute myeloid leukemia","volume":"119","author":"AFT Ribeiro","year":"2012","journal-title":"Blood"},{"issue":"2","key":"pone.0328412.ref047","first-page":"139","article-title":"RUNX1 mutations in the leukemic progression of severe congenital neutropenia","volume":"43","author":"PA Olofsen","year":"2020","journal-title":"Mol Cells"},{"issue":"5","key":"pone.0328412.ref048","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.cell.2017.01.021","article-title":"CpG Island hypermethylation mediated by DNMT3A is a consequence of AML progression","volume":"168","author":"DH Spencer","year":"2017","journal-title":"Cell"},{"issue":"3","key":"pone.0328412.ref049","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1182\/bloodadvances.2018024422","article-title":"RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs","volume":"3","author":"M Gerritsen","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"pone.0328412.ref050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41389-019-0148-9","article-title":"Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia","volume":"8","author":"C Larrue","year":"2019","journal-title":"Oncogenesis"},{"issue":"9","key":"pone.0328412.ref051","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.3390\/ijms23094694","article-title":"Mutated KIT tyrosine kinase as a novel molecular target in acute myeloid leukemia","volume":"23","author":"S Katagiri","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T17:35:05Z","timestamp":1754069705000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328412"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0328412","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}